<SEC-DOCUMENT>0001193125-13-322803.txt : 20130807
<SEC-HEADER>0001193125-13-322803.hdr.sgml : 20130807
<ACCEPTANCE-DATETIME>20130807060959
ACCESSION NUMBER:		0001193125-13-322803
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130805
ITEM INFORMATION:		Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130807
DATE AS OF CHANGE:		20130807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		131015688

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d579773d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, DC 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;5, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Orthofix International N.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cura&ccedil;ao</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-19961</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 Abraham de Veerstraat</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Cura&ccedil;ao</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: 011-59-99-465-8525 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;4.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review</U>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As previously disclosed, the Audit Committee (the &#147;<U>Audit Committee</U>&#148;) of the Board of Directors (the
&#147;<U>Board</U>&#148;) of Orthofix International N.V. (the &#147;<U>Company</U>&#148;) has commenced an independent review, with the assistance of outside professionals, of matters relating to revenue recognition for prior periods. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although the Audit Committee review remains at a preliminary stage, on August&nbsp;5, 2013, the Audit Committee concluded, after
consultation with management and the Company&#146;s independent registered public accounting firm, that certain revenues recognized during 2011 and 2012, upon further evaluation, should not have been recognized or should not have been recognized
during the periods in which they were recognized. As a result of the foregoing, on August&nbsp;5, 2013, the Audit Committee concluded, after consultation with management and the outside auditors, that the Company&#146;s previously issued
consolidated financial statements as of and for the fiscal years ended December&nbsp;31, 2011 and December&nbsp;31, 2012 (as well as the interim quarterly periods within such years), as well as for the interim quarterly period ended March&nbsp;31,
2013, should no longer be relied upon. On August&nbsp;6, 2013, the Board ratified the foregoing conclusion by the Audit Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management continues to assess the Company&#146;s disclosure controls and procedures and internal control over financial reporting for current and prior periods. Management does not expect to reach a
final conclusion on the effectiveness of the Company&#146;s internal control over financial reporting and disclosure controls and procedures until completion of the restatement process, but expects to report in future or amended filings the
existence of one or more material weaknesses in the Company&#146;s internal control over financial reporting relating to the restatement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee is continuing its review. At this time, the Company cannot predict the aggregate amount of revenue that will ultimately be restated, whether additional periods beyond those referenced
above will be affected, the final outcome or timing of the Audit Committee&#146;s continuing review of these matters, or the timing of the Company&#146;s filing of restated financial statements for the affected annual and quarterly periods.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Regulation FD Disclosure</U>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;6, 2013, the Company issued a press release regarding the matters described above.&nbsp;A copy of the press release is furnished as Exhibit&nbsp;99.1 to this Form&nbsp;8-K. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information included in this Current Report on Form&nbsp;8-K under this Item&nbsp;7.01 (including Exhibit&nbsp;99.1) shall not be
deemed &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Financial Statements and Exhibits</U>. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated August&nbsp;6, 2013</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orthofix International N.V.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jeffrey M. Schumm</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jeffrey M. Schumm</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief
Administrative Officer, General</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Counsel and Corporate Secretary</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;6, 2013 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated August&nbsp;6, 2013</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d579773dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g579773g65h61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Orthofix Issues Financial Statement Non-Reliance Statement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&#149; <B>Company to Restate Financial Statements for Fiscal Years 2011 and 2012 and First Quarter 2013 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lewisville, TX, August&nbsp;6, 2013 &#150; Orthofix International N.V. (NASDAQ:OFIX) (the &#147;Company&#148;) today provided an update regarding the
previously disclosed independent review being conducted by the Audit Committee (the &#147;Audit Committee&#148;) of the Company&#146;s Board of Directors (the &#147;Board&#148;), with the assistance of outside professionals, of matters relating to
revenue recognition for prior periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although the Audit Committee review remains at a preliminary stage, on August&nbsp;5, 2013, the Audit
Committee concluded, after consultation with management and the Company&#146;s independent registered public accounting firm, that certain revenues recognized during 2011 and 2012, upon further evaluation, should not have been recognized or should
not have been recognized during the periods in which they were recognized. As a result of the foregoing, on August&nbsp;5, 2013, the Audit Committee concluded, after consultation with management and the outside auditors, that the Company&#146;s
previously issued consolidated financial statements as of and for the fiscal years ended December&nbsp;31, 2011 and December&nbsp;31, 2012 (as well as the interim quarterly periods within such years), as well as for the interim quarterly period
ended March&nbsp;31, 2013, should no longer be relied upon. On August&nbsp;6, 2013, the Board ratified the foregoing conclusion by the Audit Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management continues to assess the Company&#146;s disclosure controls and procedures and internal control over financial reporting for current and prior periods. Management does not expect to reach a
final conclusion on the effectiveness of the Company&#146;s internal control over financial reporting and disclosure controls and procedures until completion of the restatement process, but expects to report in future or amended filings the
existence of one or more material weaknesses in the Company&#146;s internal control over financial reporting relating to the restatement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Audit Committee is continuing its review. At this time, the Company cannot predict the aggregate amount of revenue that will ultimately be restated, whether additional periods beyond those referenced above will be affected, the final outcome or
timing of the Audit Committee&#146;s continuing review of these matters, or the timing of the Company&#146;s filing of restated financial statements for the affected annual and quarterly periods. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are focused on achieving our key priorities and providing customers with the highest level of products and service they have come to expect from
Orthofix,&#148; said Brad Mason, Orthofix President and Chief Executive Officer. &#147;Our commitment to developing and delivering innovative orthopedic solutions remains unwavering and, thanks to the hard work and dedication of our employees, we
remain confident with respect to the Company&#146;s future prospects.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>About Orthofix: </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative orthopedic solutions that
drive value for patients, surgeons, and providers. Orthofix&#146;s products are widely distributed around the world to surgeons and patients via Orthofix&#146;s sales representatives and its subsidiaries, and via collaborations with other leading
orthopedic product companies. In addition, Orthofix is collaborating on R&amp;D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation and Texas Scottish Rite Hospital for Children. For more
information about Orthofix, please visit www.orthofix.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Forward-Looking Statements: </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management's current expectations and estimates
and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The forward-looking statements in this release do not constitute guarantees or promises of future
performance. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the uncertain results and timing of our audit committee&#146;s review of matters relating to revenue recognition for prior
periods, our expected inability to timely file our quarterly report on Form 10-Q for the fiscal quarter ended June&nbsp;30, 2013 (including our expected filing of a Form 12b-25 (Notification of Late Filing) with the SEC with respect to such fiscal
quarter), and our expected need to file restated financial statements for certain periods, as well how these matters may impact our expenses, liquidity, legal liability, borrowing ability, product sales, relationships with customers, suppliers,
strategic partners and third party reimbursement providers, ongoing compliance obligations under our corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services, deferred prosecution agreement
with the U.S. Department of Justice and consent decree with the SEC, ability to remain in compliance with covenants and other obligations under our senior secured credit agreement, the cost and nature of our insurance coverage, continued listing of
our securities on the Nasdaq Stock Market, and other factors described in our annual report on Form 10-K for the fiscal year ended December&nbsp;31, 2012 and other subsequent periodic reports filed by the Company with the SEC. Existing and
prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Contact: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mark Quick </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director of Investor Relations and Business Development </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>markquick@orthofix.com </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">214-937-2924 </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Source: </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orthofix International N.V. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g579773g65h61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g579773g65h61.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!``9@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:HKBY@M(
M&GN9DAB099W;`%2,"5(4X/8D9K#U#PCIVKOOU22YNV'0/,55?HJX`JHJ-_>9
M,G)+W4<UK_Q0ABW6^AQ><_3[1*,(/H.I_'%>>ZAJVHZI,TM]>2SLQSAF^4?0
M=!7HU]\,M'O87?1[UX74E<%_,3(['N/SKSW6-$O]!O3:W\/EL>4<<JX]0:]C
M#.AM#?SW/%Q7UC>>WEL5(+FXM7\RWGDA?^]&Y4_I77^'_B3J6GR+%JA-];="
MQ_UJ^^>_X_G7&45TSIPJ*TD<M.K.F[Q9]#6&H6NJ64=Y9S++#(,JP_D?0U9K
MQ;P1XG?P_JJPS.?L%RP653T0]G']?:O:`01D'(->)B*+I2MT/>P]=5H7ZBT4
M4A.!DUSG0+17.:I\0?">CR-'>:Y;"1>L<1,C#ZA<XK%;XT^"P<"[N6]Q;-0!
MWM%<-;_&+P5.X4ZC+#[R6[@?H#73Z5XAT;7$WZ7J=M=XZB*0%A]1U%`&E111
M0`45F:GXDT313C4]5M+5O[LLH#?EUK%;XI>"58@Z_#D>D<A_]EH`ZVBN2'Q2
M\$L0!K\//K'(/_9:VM+\2:)K7&F:K:7;?W8I06'X=:`-.BLC7?%6B>&O)_MB
M_2T\_/E[E8[L8ST!]163_P`+3\$?]!^+_OU)_P#$T`=;17)?\+3\$?\`0?B_
M[]2?_$T?\+3\$?\`0?B_[]2?_$T`=;17)?\`"T_!'_0?B_[]2?\`Q-7=(\=^
M&->OUL-+U:.YN7!98U1P2`,GJ`*`.@HKE)/BAX*BD:-]>B#(2K#RI."/^`UN
M:/K6G:_8"^TNZ6YMBQ42*I`R.HY`H`OT45FZWXATGPY:I<ZO>+:0R/L5F5CE
ML$XX![`T`:5%<O:_$GP?>W<-I;:W%)-.XCC01R#<Q.`.5]:ZB@`HK/U77M(T
M.,2:IJ5M:`]!+(`3]!U-<O<_&+P5;OM&I23>\5NY'Z@4`=Q17!#XT^"R<&[N
M1[FV:MC3/B)X2U9UCM=<MA(W1)28B?\`OK&:`.EHI`0P!!!!Y!%+0`45#=7E
MK8PF:[N8K>(=7E<*/S-<]<?$CP;;,5D\0VA(_P">9+_^@@T`=/17)?\`"T_!
M'_0?B_[]2?\`Q-'_``M/P1_T'XO^_4G_`,30!UM%8-KXW\-WNDW>JV^JQR65
MF0)Y0C@(3TXQGOVJA_PM/P1_T'XO^_4G_P`30!UM%8FI>,?#^CV=I>7^HK!;
MWJ[X)3&Y5Q@'J!QP>AK-'Q2\$D@#7X>?6.0?^RT`=;138Y$EC62-U='`964Y
M!!Z$&G4`%%<[JGC[PKHM^]AJ&LPPW,>-\>UF*Y]<`\^U)IGC_P`+:S?1V.G:
MLEQ<29VHD4G;DG)7`'N:`.CHK+A\2:1<3I#'>`F1MD;E&$;MZ*Y&TGZ&B@"#
M7?%FD^'T(NY]\^/E@B^9S_A^->9^(/'VK:UNAA?[%:GCRXF^9A_M-_ABN9EE
M>>>2:1BSR,68GN33:]RCA84]7JSP:V,J5-%HCV/X:,#X.B`[32`_G6WKFB6F
MOZ;)97:\'E'`^:-NQ%<?\)[\/87NGLWS12"51[,,']1^M>@UY=>\*S:[GJX>
MTZ$4^Q\]ZIIMQI&I3V%TN)86P3V8=B/8BJE>G?%31EDL[?68E^>%O*E([J>A
M_`_SKS&O9H5/:P4CQ,12]E4<0(S7M7@'5FU7PM`96W36Q,#DGDXZ'\L5XK7H
M_P`)+@XU.V/3,;C]0?Z5AC8WI7[&^!GRU;=ST<D*I9B`!R2>U?.GQ&^)E_XC
MU&?3],N7M](B8HHC.#<8_B8^A[#TKVOQ[>26'@36;B(E7%JZJ1VW?+G]:^5*
M\4]TW/"O@_5_&&H&UTR$;4P99Y#B.(>Y]?8<UZ=:?L_VXA'VW7Y#)W$,`"C\
MSS76_"/2X=-^'MA)&H$EYNGE8#EB20/R`%=K0!X;K7P%O[:W>;1M5CO&49$$
MT?ELWL&R1GZXKR[-_HVI$`S65Y;.0<$H\;#^5?8=?/\`\==,AM/%]M>Q*%:]
MM@TF.[*2,_EC\J`.Y^%'Q$F\56\FE:JP.I6J;UEX'GITR1_>'&?7/UK/^+_Q
M#O-$D3P_HTQAN9(P]S<+]Z-3T5?0GKGTQ7FGPPO)++XB:0\;8\R;RF'J&!!_
MG3/B5<-<_$36G8D[;C8/HH"_TH`P[*QU#7=32UM(9;R\N&X4?,S'N23_`#->
MC6/P%UZ>%7O-2LK5CU0;I"/RP*R?ACXRT/P7/?7>I6ES/<SJJ1-"JG8O);J1
MU./RKT+_`(7SX:_Z!^I?]\)_\50!R=Y\!=?AA9[74K*Y<=(SN0M^)&*\V=;O
M2M0="9+:[MI"IVMAHW4X/([@U[9>_'W24A;[!H]W++CY?.947/O@DUXG?7DV
MIZE<7LP!FNI6D8*.-S')P/QH`]:L])U'XQ^#].FGU*.WO-*ED@GDDC+>=D*5
M;COCK[U#_P`,_P"H?]!^V_[\-_C7:_"#PY=^'O!H-]&T5Q?3&X,3#!12`%!'
M8X&?QKNZ`/EOQSX'G\#WEK;3WT=V;F,N"B%=N#CO69X8T*3Q-XBM-&BG6W>Z
M+`2,N0N%+=/PKT3X_P#_`"&](_Z]G_\`0JY3X4_\E+T?_?D_]%O0!UW_``S_
M`*A_T'[;_OPW^-=#X&^$MYX1\31:O-JT-RD<;H8TB*D[ACJ37I]%`'QYJ7_(
M4N_^N[_^A&OH/X)_\D\B_P"OF7^8KY\U+_D*7?\`UW?_`-"-=YX*^+)\'^'D
MTD:.+K;*TGF>?L^]VQM-`'T/7EWQZ_Y%*Q_Z_1_Z`U9'_#03?]"X/_`O_P"Q
MKF/'GQ//C;2(+`Z4+/R9Q+O\[?G@C&,#UH`YOP=_R.>B_P#7]#_Z&*]Q^*OQ
M!D\)646GZ8R_VG=J6#D9\E.F['J3P/H:\.\'?\CGHO\`U_0_^ABM?XKWDEY\
M1M4\P\0LL2#T`4?UR?QH`YB::^U?4-\TDUY=W#XRQ+N[$\#U->G:#\"-2O+9
M)]9U)+`N,^1&GF.OU.0`?IFL[X'Z7#?>-I+J90WV&V:6,$=')"@_@":^AJ`/
M'KK]G^V,1^R:_*LG;S;<$'\B*\T\6^"M8\&WB0ZE&K12Y\FXB.4DQ_(^QKZL
MKD/BIIL.I?#W4_-0%K9!/&3_``LI_P`,C\:`/'?A[\2M0\+7\-G?3R7&D2,%
M>-SDPY_B3TQW'0U[QXF\1VWASPS<ZW)B5(HP8E!_UC'A0#[DC\*^3*]2\::M
M/<_!?PK&[G,SX;)Y81AE']*`.!U_Q)JOB;4'O=4NWF<DE4S\D8]%'85U?AWX
M-^(]=LH[V9H-.@E4,GGY+L#T.T=/QQ7%:5<6UIJUI<WD!GMX9E>6($`NH.2.
M?6O9_P#A?^F?]`&Z_P"_R_X4`9J_L_7>/F\0P@^UL3_[-2_\,_7/_0Q1?^`I
M_P#BJT?^&@--_P"@%=?]_E_PK6\+_&&Q\3^(;;1X=(N('N"V)'E4A<*6Z?A0
M!D7_`(&D\#?"GQ+;27ZWAN?+<,L>S;AE&.IKP^OI_P"*7_)-M9_ZY)_Z&M?,
M%`'U/INBV'B#X>:=IFI0":WFL(@0>JG8,,#V(]:^?/&W@J_\%ZN;6X!EM9"3
M;7(7`D7T]F'<5](^$_\`D4='_P"O*'_T`4_Q#X>T_P`3Z1+IFI1;XGY5A]Z-
MNS*>Q%`'C?PH^)9TF6/P]K4_^@N<6T[G_4$_PD_W3^GTZ=S\3?B+%X3L38:?
M(LFKW"94#D0*?XS[^@_'Z^'>+O"E]X/UM]-O<."-\,J])4SP?;ITK'9IKNX!
M=VEE<A=SMDGL.3^%`$]I:7^NZJEO;I)=WMW)P,Y9V/))/ZDU]">&_AS'X8\'
M7MK;[)M7O+<K--G&[C_5J>R]L_C4GPV^'EOX/T\7=V$FU:X7][(.1$/[BG^9
M[_2NYH`\H;37NM;O9;=&=[PW"0V8C,<MLS(BQL_'"J58XSA2`1G-%>KT4`?/
M>JVAT_6+RS(QY$SH/H#Q^E5*[?XGZ,;36H]4C7]U>+M<CM(H_J,?D:XBOHJ4
M^>"D?-5H>SJ.)L^%-;/A_7X+QB?(;]W,!_</?\.#^%>Z1R)+&LD;!D<!E8'@
M@]Z^<J[[P%XW2P5-'U63;;YQ!.QXC_V3[>A[5R8R@YKGCNCLP6(4'R2V9WOB
M:S%_X:U"V(SN@8CZ@9'ZBO!!T%?0]XR_V?.Q(*>4QR#U&*^>!TJ<`_=DBLQ2
MYHL*]&^$D#9U.X_A_=H/<\D_TKSFO;/`FC-HWAF%)EVSW!\Z0'J">@_`8K7&
MS4:5NYC@8.56_8L^,=-DU?P?JMA$-TLUJXC'JP&0/S`KY-((.",$5]F5XK\1
MOA%=RWTVL^&H1,DS%YK)>&5CU*>H/I^7MXI[IU?P:UZWU3P1!8"0?:=.)BD3
M/.TDE6^F#C\*[^OD:SO-;\*:J)[=[G3;V+@[E*'Z$'J/8UV]I\=?%$$02>UL
M+EA_&T;*3^1Q0!]!5\Z?&?7X-9\9BVM9%DBT^+R"RG(+Y);\L@?@:K:W\7_%
MFM6[VPN8K&%QAA:IM8CTW$DC\,5S^A^%-=\27`CTS3IY]QYE*XC7W+'@4`;'
MPHTV74?B'INP'9;,T\A]`H./U('XU1^(/_(_ZY_U^/\`SKWGX=^`(/!.FN9)
M%N-1N<>?,HX`'1%]OYUX)X_</X^UPC_G]D'Y'%`'2?##X>Z7XULK^?4+FZA:
MVD1$$#*`003SD'TKN&^`OAPJ0NHZB#C@ED./_':I?L__`/(*UG_KO'_Z":]=
MH`^2?$WAR^\*ZY/I=^OSQG*2`?+*AZ,/8UZ'\%;WPQ+>?V??:;;+K"DO;74@
MW&0>@SP&'MU'TKT?XA>"+?QGH9B4+'J%N"UK,?7NI_V3^G6OFB2.]T;4S&XD
MM+VTEP1]UHW4_P`\T`?8=%<3\-?'\/C'2A!=,D>JVR@3Q]/,']]1Z>OH?J*[
M:@#PSX__`/(;TC_KV?\`]"KE/A3_`,E+T?\`WY/_`$6]=7\?_P#D.:3_`->S
M_P#H5<I\*?\`DI>C_P"_)_Z+>@#Z>HHHH`^/-2_Y"EW_`-=W_P#0C7KWPP^'
MOAGQ)X.CU#5+!IKDSR(7$SKP#QP#7D.I?\A.[_Z[/_Z$:^@_@G_R3R+_`*^9
M?YB@"S_PI_P1_P!`I_\`P)D_QKA?BUX%\/>%_#MK=Z19-!-)="-F,K-E=K'&
M"?85[C7EWQ[/_%)6'_7Z/_0&H`\=\'?\CGHO_7]#_P"ABM[XOZ9)I_Q#O9&4
MB.\5)XSZ@J`?U!K`\'G'C/1<_P#/]#_Z&*^B/B!X$MO&VE+'O6"_M\FVG(X&
M>JM_LG]*`/&_@[KT&B>-TCNI!'#?Q&WW,<`,2"N?Q&/QKZ0KY,U[PCKWAJ=H
M]3TZ:)0>)E7=&WN&'%;VA?%WQ9HELEM]IBOH8QA5NTW,!Z;@0?SS0!]*UPGQ
M?UZWTGP-=6C2#[3J.((DSR1D%C]`/YBO.;KX[>)YHML%II]NQ_C6-F(_-L5P
M]_J.M^*]4\^[DN=1O'X`52Q`]%4=![`4`9E>G_$/39=)^&/@^SF4K(BNSJ>H
M+`,1^M7?AY\'[U[Z#5O$T/D01,'CLFY>0CIO]![=36G^T!_R"]&'_3:7_P!!
M6@#R7PMI]OJOBG3-/NU9H+FY2.0*<$J3@\U[S_PI;P7_`,^MU_X$M7A_@7_D
M>]#_`.OZ+_T(5]74`<#_`,*6\%_\^MU_X$M5_1/A?X8\/ZM#JFGV]PES!G86
MG9AR"#Q]#77T4`<E\4O^2;:S_P!<D_\`0UKY@KZ?^*7_`"3;6?\`KDG_`*,6
MOF"@#ZU\)_\`(HZ/_P!>4/\`Z`*SO'/CFP\%:5YTV)KV8$6UL#RY]3Z*.YK+
MNO&^G>#/AWI%Q<,LUW+81?9K8-\TAV#D^BCN:^?M9UG4?$>K2ZAJ$S3W,[?@
M!V51V`["@!VI:EJGBC7'N[IGNKV[D`"J,Y)X"J/3L!5KQ-X1U?PE<00ZK`$^
MT1B1'0Y4^JY]1W%>Q_"KX:C0($US6(0=3E7,,3#_`(]E/_LQ_3IZUVOBGPQ8
M>+-$ETR_7`;YHI0/FB?LP_SR*`/+/A1\3_(,/AS7I_W1^6TNI&^[Z(Q]/0]N
MGT]LKY&\1>'[_P`,:S-I>H1[98C\K#[LB]F'L:]7^%/Q/$RP^'-?N/W@PEI=
M2'[WHC'U]#WZ?4`]BHHHH`SM>T:#7M(FT^?@2#*/W1AT->%ZEIMUI%_+8WD9
MCFB.#Z,.Q'J#7T+6-XB\,:?XDMA'=J4F0?NYT^\G^(]J[,-B/9.TMCBQ6&]L
MKQW/":U=$\-:KX@DVV-L3%G#3/\`*B_CW^@KT+1?ACIUC+YVI3&_8'Y8]NU/
MQ'?^5=K'''!$$C18XT&`JC`45U5<=%:4]3DHX"3UJ:'&W5G+X-\`WL5QJ4MV
M[Q^7&'^ZA;C"]\<YZ]J\F16=E1%+,QPJJ,D_A7JWB'2=4\:ZA%;PG[)I%LV?
M/D',S]RJ]P.@)XZUNZ%X3TGP^@-K!OGQ\T\OS.?\/PJ*>(C2@W+63-*F'E6F
ME'2*.+\&_#^Y:[CU+6H?*BC(:.W;[SGL6'8#TKT^BBN&K5E5E>1W4:,:4>6(
M4445D;$%U8V=\FR[M8;A?26,,/UK*?P3X5D8L_AS3&8]S:I_A6Y10!D6WA/P
MY9MNM]"TZ(^JVR#^E:J(L:A$4*HX``P!3J*`"JDFE:=+(TDFGVKNQRS-"I)/
MN<5;HH`AM[2VM`PMK>*$-R1&@7/Y5-110`55ETS3YY#+-8VTDC=6>)23^)%6
MJ*`*T&G6-M)YEO96\+XQNCB53CZ@59HHH`@N+&TNV#7-K#,5&`9(PV/SID6F
M:?!*)8;&VCD7HR1*"/Q`JU10`4444`4SH^EL23IMH2>I,"_X58@MX;:/R[>&
M.),YVQJ%'Y"I**`"HKBUM[I`ES!',H.0LB!@#^-2T4`5$TG38W5TT^U5E.0R
MPJ"#^56Z**`&LJNI5E#*>"",@UEW/A3P[>-NN="T^4^K6R'^E:U%`&&G@CPJ
MC!E\.:8".XM4_P`*U+6PL[%=MI:06Z^D483^56**`"H;BTMKL*+FWBF"\@2(
M&Q^=344`5(]*TZ*19(]/M4=3E66%00?KBK=%%`!1110`R6*.>-HIHUD1NJNH
M(/X&JO\`8VE_]`VT_P"_"_X5=HH`K2Z;83[?.LK>38NU=\2G:/0<=*8NDZ8C
MATTZU5E.01"H(/Y5<HH`****`*]Q8V=VP:YM()F48!DC#$#\:C&CZ6""--M`
/1R#Y"_X5<HH`****`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
